ecrin-mdr-crcClinical2006Lung CancerColorectal CancerFatigueDepressionDepressive DisorderLiver CancerPancreatic CancerGallbladder CancerLiver NeoplasmsExtrahepatic Bile Duct CancerLung NeoplasmsEsophageal NeoplasmsGallbladder NeoplasmsBile Duct NeoplasmsGastric CancerEsophageal CancerPancreatic NeoplasmsStomach NeoplasmsCholangiocarcinomaLung CancerColorectal CancerFatigueDepressionDepressive DisorderLiver CancerPancreatic CancerGallbladder CancerLiver NeoplasmsExtrahepatic Bile Duct CancerLung NeoplasmsEsophageal NeoplasmsGallbladder NeoplasmsBile Duct NeoplasmsGastric CancerEsophageal CancerPancreatic NeoplasmsStomach NeoplasmsCholangiocarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2033517United States3Advanced adult primary liver cancerStage IVB rectal cancerStage IV pancreatic cancerUnresectable extrahepatic bile duct cancerEscitalopramStage IVA rectal cancerStage IV esophageal cancerCitalopramStage IV non-small cell lung cancerDexetimidePsychosocial effects of cancer and its treatmentStage IVA colon cancerStage III pancreatic cancerStage IVB colon cancerExtensive stage small cell lung cancerStage IIIB non-small cell lung cancerUnresectable gallbladder cancerStage IV gastric cancerECRIN MDRTerminatedfalseEscitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal CancerRATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer. It is not yet known whether escitalopram is more effective than a placebo in treating depression in patients with advanced lung or gastrointestinal cancer. PURPOSE: This randomized clinical trial is studying the side effects of escitalopram and to see how well it works compared to a placebo in treating depression in patients with advanced lung or gastrointestinal cancer.2006-03-152033517NCT00387348